In the non-obesity group, multivariate analysis demonstrated that anlotinib therapy (p = 0.002), PS score of 0 (p = 0.005), EGFR mutation (p = 0.022), number of metastases ≤3 (p < 0.001), and less lines of previous chemotherapy (p = 0.013) were independent predictors of improved OS (Table 2). Here, EGFR is linked to obesity disorder.